StockTipsArenaBeta

BUY Aurobindo Pharma — Amit Seth

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byAmit SethHorizon: NA (inferred Intraday)30 Jul 2026, 9:43 am ISTvia CNBC Awaaz.

Entry₹1,601.5Inferred
Target₹1,640
Total upside +2.40% (call closed)
Stop loss₹1,580-1.34% risk
Exit₹1,58030 Jul 2026, 2:07 pm
Stop-loss hit-1.34%
Follow Amit Seth for new calls(4% target hit, 81 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 30 Jul 2026
3 supporting2 neutral0 opposing
Supports the BUY call (3)

2 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·29 Jul · today

Aurobindo Pharma has signed a non-exclusive voluntary license agreement with MSD to supply generic alimatravir to 129 Low- & Middle-Income Countries (LMICs). This royalty-free agreement aims to expand

BSE · Company Update·24 Jul · 5d ago

(opens in new tab)

Aurobindo Pharma is acquiring majority ownership control in A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA, expanding its business.

BSE · Company Update·23 Jul · 6d ago

(opens in new tab)
Neutral / worth noting (2)

Aurobindo Pharma signs licensing pact with Merck to supply generic HIV drug in 129 countries

NewsCnbc-Tv18·24 Jul · 5d ago

(opens in new tab)

Aurobindo Pharma arm Apitoria to acquire 80% stake in A1 Biochem Group for $17 million

NewsCnbc-Tv18·23 Jul · 6d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Amit Seth

Every call and its outcome